Becton, Dickinson and Company (BDX)
BD and Ypsomed Expand Partnership to Target Growing Biologics Market
BDX expands its Ypsomed partnership with a 5.5 mL Neopak XtraFlow syringe, targeting rising demand for large-volume subcutaneous self-injection.
BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System
BDX wins FDA 510(k) clearance for the EnCor EnCompass breast biopsy system, set for an early 2026 launch to boost flexibility and patient care.
Why The ‘Magnificent 7' Is Out In 2026 And These 3 Dividends Are ‘In'
Ignore the doom-and-gloom “predictions” about 2026. There are plenty of gains—and growing dividends—to be had for us this year.
BD and Penn Institute Ink Collaboration to Advance Immunotherapy
BDX teams up with the Penn Institute for Immunology and Immune Health to launch a high-parameter immune profiling study.
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BDX Unveils Portable PureWick System for On-the-Go Incontinence Care
BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.
Becton, Dickinson and Company (BDX) Q4 2025 Earnings Call Transcript
Becton, Dickinson and Company ( BDX ) Q4 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Adam Reiffe Thomas Polen - President, CEO & Chairman Christopher DelOrefice - Executive VP & CFO Conference Call Participants Travis Steed - BofA Securities, Research Division Patrick Wood - Morgan Stanley, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, and welcome to BD's Fourth Quarter and Full Year Fiscal 2025 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 839-2383 for domestic calls and area code +1 402 220-7202 for international calls.
BD Stock Slips in Pre-Market Despite Q4 Earnings Beat, Margins Up
BDX tops fourth-quarter fiscal 2025 earnings estimates and posts strong margin gains, with growth across all business segments and geographies.
Becton Dickinson (BDX) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton Dickinson (BDX) Tops Q4 Earnings and Revenue Estimates
Becton Dickinson (BDX) came out with quarterly earnings of $3.96 per share, beating the Zacks Consensus Estimate of $3.92 per share. This compares to earnings of $3.81 per share a year ago.
